Perceptive Advisors LLC Purchases Shares of 1,286,862 Evolus, Inc. $EOLS

Perceptive Advisors LLC acquired a new stake in Evolus, Inc. (NASDAQ:EOLS) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,286,862 shares of the company’s stock, valued at approximately $5,289,000.

Several other institutional investors also recently modified their holdings of EOLS. Larson Financial Group LLC raised its holdings in shares of Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares during the period. Meeder Asset Management Inc. acquired a new stake in Evolus in the 4th quarter valued at about $34,000. Wexford Capital LP bought a new position in Evolus during the third quarter worth about $37,000. Aquatic Capital Management LLC bought a new position in Evolus during the third quarter worth about $48,000. Finally, State of Wyoming acquired a new position in Evolus during the fourth quarter worth approximately $63,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Price Performance

NASDAQ:EOLS opened at $5.84 on Friday. The company has a market cap of $384.62 million, a P/E ratio of -8.72 and a beta of 1.32. The firm’s fifty day moving average price is $6.47 and its two-hundred day moving average price is $5.49. Evolus, Inc. has a one year low of $3.86 and a one year high of $9.35.

Evolus (NASDAQ:EOLS) last posted its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same period in the previous year, the company posted ($0.30) EPS. As a group, equities research analysts expect that Evolus, Inc. will post -0.38 earnings per share for the current year.

Wall Street Analyst Weigh In

EOLS has been the topic of several research analyst reports. BTIG Research restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.